Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Switching to Viramune Is Possible at Higher CD4s

February 1, 2011

Current U.S. Guidelines state that Viramune (nevirapine) should not be started in women with CD4s above 250 and in men with CD4s above 400. This is due to potentially severe allergic reactions found mostly at higher CD4 counts. However, there's no guidance around switching someone to a regimen with Viramune after already having been on treatment for awhile.

In 2010, the European Medicines Agency, who reviewed data from more than 12,000 patients in several large studies such as EuroSIDA, ATHENA and others, now recommends that women and men can switch to Viramune regardless of their CD4 counts provided that their viral loads are undetectable. Sometimes Viramune may be a better choice for certain individuals due to the side effects, drug interactions or resistance with other drugs.

People who wish to switch to Viramune should consult their doctors and weigh the pros and cons with this information. This change was not incorporated into the latest update to the U.S. Guidelines in January 2011.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Nevirapine (Viramune)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement